测量差异解释缺血性卒中后依从性与持续性的多数变异,标准化估计值更低:一项系统综述与元回归
该系统综述纳入141项研究,其中101项(432个估计值,976,020名参与者)进入定量合成。未标准化汇总估计显示74.1%的患者依从、76.8%持续用药;在预设参考测量框架下模型估计降至53.7%和48.2%,提示异质性主要源于定义与测量方法的不一致。
要点
- 未标准化汇总的依从/持续比例偏高,标准化后依从53.7%、持续48.2%。
- 异质性更多集中于测量相关的评估与实施领域,而非患者特征。
- 标准化持续率从1-4个月的63.3%降至30个月以上的28.1%。
核心结论
- 缺血性卒中或TIA后用药依从性与持续性的异质性大部分可归因于结局定义与测量方法的方法学不等价。
- 在标准化框架下,用药继续不佳比传统汇总估计所显示的更为常见。
研究设计与样本
- 系统综述与元回归,检索 bibliographic databases、学位论文和试验注册库至2025年9月10日。
- 纳入报告缺血性卒中或TIA后二级预防药物依从性或持续性的常规诊疗研究。
- 定量合成纳入101项研究(432个估计值,976,020名参与者),采用三水平分层贝叶斯模型与多变量元回归。
主要发现
- 未标准化汇总估计:74.1%的患者依从,76.8%的患者持续用药。
- 异质性显著,解释的变异更多集中于测量相关的Assessment和Administration领域,而非报告的患者特征。
- 参考规格(药房或行政数据、中等定义严格度、9-15个月随访窗口)下模型估计:依从53.7%,持续48.2%。
- 标准化持续率从1-4个月的63.3%降至30个月以上的28.1%。
- 调整后估计在亚洲总体较低;抗凝药的持续性数值最低,但可信区间宽且重叠。
关键数值与推荐
- 预设参考测量框架:药房或行政数据、中等定义严格度、9-15个月随访窗口。
- 标准化模型估计依从53.7%、持续48.2%,低于未标准化汇总的74.1%和76.8%。
- 标准化持续率:1-4个月63.3%,30个月以上28.1%。
临床怎么用
- 解读卒中后用药依从性与持续性文献时需关注定义与测量方法的差异,避免直接比较不同测量框架下的估计值。
- 监测与基准比较应采用纵向、标准化且透明的用药持续性测量,而非仅依赖出院处方。
局限性
- 抗凝药持续性的可信区间宽且重叠,相关比较需谨慎解读。
- 标准化估计基于预设参考规格的模型推导,可能受参考规格选择影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Continued use of secondary prevention medications after ischemic stroke or transient ischemic attack is an important component of long-term management. Reported estimates of adherence and persistence vary considerably across studies, limiting comparison and interpretability. Although some variation may reflect differences in patient behavior, inconsistencies in operational definitions and measurement approaches are also likely to contribute. We sought to examine sources of heterogeneity and to derive standardized estimates using a common reference measurement framework. STUDY DESIGN AND SETTING: We searched bibliographic databases, dissertations, and trial registries from inception to September 10, 2025, for routine-care studies reporting adherence or persistence to secondary prevention medications after ischemic stroke or transient ischemic attack. Cutoff-based proportions were extracted. We used 3-level hierarchical Bayesian models to characterize heterogeneity and multivariable meta-regression to evaluate associations with measurement specifications, follow-up window, medication class, region, and study-level characteristics. From the fitted model, we derived estimates standardized to a prespecified reference specification: pharmacy or administrative data, moderate definition stringency, and a 9- to 15-month follow-up window. RESULTS: The review included 141 studies; 101 (432 estimates; 976,020 participants) contributed to the quantitative synthesis. Unstandardized pooled estimates suggested that 74.1% of patients were adherent and 76.8% were persistent. Heterogeneity was substantial, with explained variation concentrated more in the measurement-related Assessment and Administration domains than in reported Patient characteristics. Under the common reference specification, the model-based estimates were lower, at 53.7% for adherence and 48.2% for persistence. Standardized persistence declined from 63.3% at 1 to 4 months to 28.1% beyond 30 months. Adjusted estimates were generally lower in Asia; persistence was numerically lowest for anticoagulants, although credible intervals were wide and overlapping. CONCLUSION: A large proportion of the heterogeneity reported in medication adherence and persistence after ischemic stroke or transient ischemic attack appears to be attributable to methodological non-equivalence in how these outcomes are defined and measured. When evaluated within a standardized framework, suboptimal medication continuation appears more common than conventional pooled estimates indicate. Meaningful surveillance and benchmarking require longitudinal, standardized, and transparent measures of medication continuation rather than reliance on discharge prescribing alone.
引用
- Jiang Y, Chen J, Liu L, et al. Measurement differences explain much of the variation in adherence and persistence after ischemic stroke, and standardized estimates are lower: a systematic review with meta-regression. J Clin Epidemiol. 2026. PMID: 42914064. doi:10.1016/j.jclinepi.2026.112571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。